Prolonged Continuous ECG Monitoring Prior to Transcatheter Aortic Valve Implantation

NCT03561805 · tracked via the Priya Life Science Canada tracker

Sponsor

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

Phase

Not applicable

Started

2017-06-01

Last updated

2026-03-27

Condition(s) studied

Aortic Valve StenosisArrythmia

Investigational drug(s) / intervention(s)

ECG monitoring

ECG monitoring: Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure

Study summary

Patients with severe aortic stenosis candidates for a TAVI procedure harbor a high burden of silent arrhythmic events. Pre-procedural detection of such arrhythmias should help the investigators to implement specific therapeutic measures that may improve patient outcomes and reduce hospitalization length post-TAVI.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients with severe aortic stenosis accepted for a TAVI procedure by the Heart Team. Exclusion Criteria: * Urgent TAVI procedure or logistic reasons precluding an ECG monitoring of at least 1 week within the 3 months prior to the TAVI procedure. * Prior permanent pacemaker.

Primary outcome measure(s)

Arrhythmic events — Within 3 months prior to the TAVI procedure
Incidence and type of arrhythmic events
Therapeutic changes — Within 3 months prior to the TAVI procedure
incidence of arrhythmic events identified by the device leading to therapeutic changes prior to the TAVI procedure

Trial sites (1)

Facility	City	Region	Status
IUCPQ	Québec	Quebec

More Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec trials in Canada

Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR Recruiting

Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure Active, not recruiting

Transcatheter Aortic Valve Replacement Versu Surgical Aortix Valve Replacement for Treating Elderly Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Prospective Randomized Study The VIVA Trial Active, not recruiting

Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atrio-Ventricular Block in Patients With New-onset PeRsistent LEft Bundle Branch Block After Transcatheter Aortic Valve Implantation. The "MARE" Study Recruiting

Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprotheses. The 'LYTEN' Trial Active, not recruiting

Other trials for the same condition

Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis. Recruiting

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients Active, not recruiting

Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach With a New LBBB After TAVI Recruiting

Effect of Fetal Aortic Valvuloplasty on Outcomes Recruiting

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03561805 on ClinicalTrials.gov ↗ ← All trials in Canada